Back to Browse Journals » Medicolegal and Bioethics » Volume 1

An analysis of the Bateson Review of research using nonhuman primates

Authors Greek R, Hansen LA, Menache A

Published 6 December 2011 Volume 2011:1 Pages 3—22

DOI https://dx.doi.org/10.2147/MB.S25938

Review by Single-blind

Peer reviewer comments 2

Ray Greek1, Lawrence A Hansen2, Andre Menache1
1Americans for Medical Advancement, Goleta, 2Department of Neurosciences, University of California, San Diego, CA, USA

Abstract: An analysis of the use of nonhuman primates in biomedical research in the UK, the Review of Research Using Non-Human Primates (the "Bateson Review") was released in 2011. The review was applauded, to varying degrees, by most of the stakeholders in the controversy over using nonhuman primates in biomedical research. However, there has not been a scientific analysis of the review. In this paper, the Bateson Review is examined for both methodology and the science relevant to the use of nonhuman primates in biomedical research. The relevant science includes complexity theory, evolutionary biology, genetics, empirical evidence regarding the reliability of interspecies extrapolation, and the value of basic biomedical research in general in making discoveries that lead to human treatments. The authors of this paper conclude that the Bateson Review does not meet the criteria for a scientific assessment, in part, because it fails to consider the current science that impacts on the practice of using animals, in general, and nonhuman primates, specifically, in biomedical research. This lack of scientific consideration has legal and ethical ramifications. Since the Bateson Review fails as a scientific evaluation, the ethical and legal recommendations that are based on science are also suspect.

Keywords:
medicine, complex, evolution, ethics, primate, research

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Metabolic biomarkers for predicting cardiovascular disease

Montgomery JE, Brown JR

Vascular Health and Risk Management 2013, 9:37-45

Published Date: 29 January 2013

Dormancy in breast cancer

Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H

Breast Cancer: Targets and Therapy 2012, 4:183-191

Published Date: 5 December 2012

Fabrication and in vitro release behavior of a novel antibacterial coating containing halogenated furanone-loaded poly(L-lactic acid) nanoparticles on microarc-oxidized titanium

Cheng YC, Wu J, Gao B, Zhao XH, Yao JY, Mei SL, Zhang L, Ren HF

International Journal of Nanomedicine 2012, 7:5641-5652

Published Date: 7 November 2012

REACH, animal testing, and the precautionary principle

Menache A, Nastrucci C

Medicolegal and Bioethics 2012, 2:13-29

Published Date: 6 August 2012

Correlation between radioactivity and chemotherapeutics of the 111In-VNB-liposome in pharmacokinetics and biodistribution in rats

Lee WC, Chang CH, Huang CM, Wu YT, Chen LC, Ho CL, Chang TJ, Lee TW, Tsai TH

International Journal of Nanomedicine 2012, 7:683-692

Published Date: 9 February 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program

R Michael Kirchner, J Dawn Abbott

Vascular Health and Risk Management 2009, 5:1089-1097

Published Date: 16 December 2009